Download PDF
Clin Colon Rectal Surg 2024; 37(03): 157-171
DOI: 10.1055/s-0043-1770385
Review Article

Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved

Dina Ioffe
1   Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
,
Michelle McSweeny
1   Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
,
Michael J. Hall
1   Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The recognized importance of microsatellite instability (MSI) in cancer has evolved considerably in the past 30 years. From its beginnings as a molecular predictor for Lynch syndrome, MSI first transitioned to a universal screening test in all colorectal and endometrial cancers, substantially increasing the identification of patients with Lynch syndrome among cancer patients. More recently, MSI has been shown to be a powerful biomarker of response to immune checkpoint blockade therapy across a diversity of tumor types, and in 2017 was granted Food and Drug Administration approval as the first tumor histology-agnostic biomarker for a cancer therapy. Focusing on colorectal cancer specifically, immune checkpoint blockade therapy has been shown to be highly effective in the treatment of both MSI-high (MSI-H) colon and rectal cancer, with data increasingly suggesting an early role for immune checkpoint blockade therapy in MSI-H colorectal tumors in the neoadjuvant setting, with the potential to avoid more toxic and morbid approaches using traditional chemotherapy, radiation therapy, and surgery. The success of MSI as an immune checkpoint blockade target has inspired ongoing vigorous research to identify new similar targets for immune checkpoint blockade therapy that may help to one day expand the reach of this revolutionary cancer therapy to a wider swath of patients and indications.

Keywords

microsatellite instability - colorectal cancer - immune checkpoint blockade


Publication History

Article published online:
25 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ligtenberg MJ, Kuiper RP, Chan TL. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 2009; 41 (01) 112-117
    CrossrefPubMedGoogle Scholar
  • 2 Win AK, Jenkins MA, Dowty JG. et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2017; 26 (03) 404-412
    CrossrefPubMedGoogle Scholar
  • 3 Aaltonen LA, Peltomäki P, Leach FS. et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260 (5109): 812-816
    CrossrefPubMedGoogle Scholar
  • 4 Boland CR, Thibodeau SN, Hamilton SR. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58 (22) 5248-5257
    PubMedGoogle Scholar
  • 5 Umar A, Boland CR, Terdiman JP. et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96 (04) 261-268
    CrossrefPubMedGoogle Scholar
  • 6 Hampel H, Frankel WL, Martin E. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352 (18) 1851-1860
    CrossrefPubMedGoogle Scholar
  • 7 Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11 (01) 42-65
    CrossrefPubMedGoogle Scholar
  • 8 Holter S, Hall MJ, Hampel H. et al. Risk assessment and genetic counseling for Lynch syndrome - practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. J Genet Couns 2022; 31 (03) 568-583
    CrossrefPubMedGoogle Scholar
  • 9 Hampel H, Frankel WL, Martin E. et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26 (35) 5783-5788
    CrossrefPubMedGoogle Scholar
  • 10 Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12 (02) 93-104
    CrossrefPubMedGoogle Scholar
  • 11 National Comprehensive Cancer Network NCCN guidelines. Genetic/Familial High-Risk Assessment: Colorectal. Version 1. 2022 . Accessed June 4, 2023 at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
    PubMedGoogle Scholar
  • 12 Loughrey MB, Waring PM, Tan A. et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6 (03) 301-310
    CrossrefPubMedGoogle Scholar
  • 13 Goodfellow PJ, Billingsley CC, Lankes HA. et al. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 2015; 33 (36) 4301-4308
    CrossrefPubMedGoogle Scholar
  • 14 Pearlman R, Haraldsdottir S, de la Chapelle A. et al. Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. J Med Genet 2019; 56 (07) 462-470
    CrossrefPubMedGoogle Scholar
  • 15 Hampel H, Pearlman R, de la Chapelle A. et al. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecol Oncol 2021; 160 (01) 161-168
    CrossrefPubMedGoogle Scholar
  • 16 Beamer LC, Grant ML, Espenschied CR. et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012; 30 (10) 1058-1063
    CrossrefPubMedGoogle Scholar
  • 17 Hall MJ. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients–will the ends justify the means?. J Natl Compr Canc Netw 2010; 8 (05) 606-611
    CrossrefPubMedGoogle Scholar
  • 18 Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 2010; 8 (05) 597-601
    CrossrefPubMedGoogle Scholar
  • 19 Shaikh T, Handorf EA, Meyer JE, Hall MJ, Esnaola NF. Mismatch repair deficiency testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. JAMA Oncol 2018; 4 (02) e173580
    CrossrefPubMedGoogle Scholar
  • 20 FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Accessed June 4, 2023 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication
    PubMedGoogle Scholar
  • 21 Kautto EA, Bonneville R, Miya J. et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 2017; 8 (05) 7452-7463
    CrossrefPubMedGoogle Scholar
  • 22 Cai Z, Wang Z, Liu C. et al. Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing. J Mol Diagn 2020; 22 (07) 860-870
    CrossrefPubMedGoogle Scholar
  • 23 Mao X, Zhang Z, Zheng X. et al. Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol 2017; 12 (04) 663-672
    CrossrefPubMedGoogle Scholar
  • 24 Latham A, Srinivasan P, Kemel Y. et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 2019; 37 (04) 286-295
    CrossrefPubMedGoogle Scholar
  • 25 Moertel CG, Fleming TR, Macdonald JS. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322 (06) 352-358
    CrossrefPubMedGoogle Scholar
  • 26 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955): 939-944
    CrossrefPubMedGoogle Scholar
  • 27 O'Connell MJ, Laurie JA, Kahn M. et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16 (01) 295-300
    CrossrefPubMedGoogle Scholar
  • 28 Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17 (05) 1356-1363
    CrossrefPubMedGoogle Scholar
  • 29 Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1 (02) 104-109
    CrossrefPubMedGoogle Scholar
  • 30 Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119 (04) 921-928
    CrossrefPubMedGoogle Scholar
  • 31 Ribic CM, Sargent DJ, Moore MJ. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (03) 247-257
    CrossrefPubMedGoogle Scholar
  • 32 Sargent DJ, Marsoni S, Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28 (20) 3219-3226
    CrossrefPubMedGoogle Scholar
  • 33 André T, Boni C, Mounedji-Boudiaf L. et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23) 2343-2351
    CrossrefPubMedGoogle Scholar
  • 34 Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370 (9604): 2020-2029
    CrossrefPubMedGoogle Scholar
  • 35 André T, de Gramont A, Vernerey D. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015; 33 (35) 4176-4187
    CrossrefPubMedGoogle Scholar
  • 36 Zaanan A, Cuilliere-Dartigues P, Guilloux A. et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21 (04) 772-780
    CrossrefPubMedGoogle Scholar
  • 37 Tougeron D, Mouillet G, Trouilloud I. et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. . J Natl Cancer Inst 2016; 108(07)
    PubMedGoogle Scholar
  • 38 Cohen R, Taieb J, Fiskum J. et al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol 2021; 39 (06) 642-651
    CrossrefPubMedGoogle Scholar
  • 39 Hutchins G, Southward K, Handley K. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29 (10) 1261-1270
    CrossrefPubMedGoogle Scholar
  • 40 Guetz GD, Uzzan B, Nicolas P, Schischmanoff P, Morere J. Microsatellite instability as a predictor of chemotherapy efficacy in colorectal cancer. J Clin Oncol 2008; 26 (15) 4117-4117
    CrossrefPubMedGoogle Scholar
  • 41 Bertagnolli MM, Niedzwiecki D, Compton CC. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27 (11) 1814-1821
    CrossrefPubMedGoogle Scholar
  • 42 Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015; 26 (01) 126-132
    CrossrefPubMedGoogle Scholar
  • 43 Pogue-Geile K, Yothers G, Taniyama Y. et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst 2013; 105 (13) 989-992
    CrossrefPubMedGoogle Scholar
  • 44 Grothey A, Sobrero AF, Shields AF. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378 (13) 1177-1188
    CrossrefPubMedGoogle Scholar
  • 45 Baxter NN, Kennedy EB, Bergsland E. et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol 2022; 40 (08) 892-910
    CrossrefPubMedGoogle Scholar
  • 46 Yunlong W, Tongtong L, Hua Z. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med 2023; 12 (03) 2440-2452
    CrossrefPubMedGoogle Scholar
  • 47 Seligmann JF. FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). J Clin Oncol 2020; 38 (15) 4013-4013
    CrossrefPubMedGoogle Scholar
  • 48 National Comprehensive Cancer Network NCCN guidelines: colon cancer. Version 1. 2022 . Accessed June 4, 2023 at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
    PubMedGoogle Scholar
  • 49 Stintzing S, Wirapati P, Lenz HJ. et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol 2019; 30 (11) 1796-1803
    CrossrefPubMedGoogle Scholar
  • 50 Shulman K, Barnett-Griness O, Friedman V. et al. Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers. JCO Precis Oncol 2018; 2 (02) 1-10
    CrossrefPubMedGoogle Scholar
  • 51 Venderbosch S, Nagtegaal ID, Maughan TS. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20 (20) 5322-5330
    CrossrefPubMedGoogle Scholar
  • 52 Tougeron D, Sueur B, Sefrioui D. et al. A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability. J Clin Oncol 2017; 35 (15) 3536
    CrossrefPubMedGoogle Scholar
  • 53 Innocenti F, Ou F-S, Zemla T. et al. Somatic DNA mutations, MSI status, mutational load (ML): association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2017; 35 (15) 3504-3504
    CrossrefPubMedGoogle Scholar
  • 54 Lenz H-J, Ou F-S, Venook AP. et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 2019; 37 (22) 1876-1885
    CrossrefPubMedGoogle Scholar
  • 55 Tougeron D, Sueur B, Zaanan A. et al; Association des Gastro-entérologues Oncologues (AGEO). Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study. Int J Cancer 2020; 147 (01) 285-296
    CrossrefPubMedGoogle Scholar
  • 56 André T, Shiu K-K, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
    CrossrefPubMedGoogle Scholar
  • 57 Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009; 29 (05) 1615-1620
    PubMedGoogle Scholar
  • 58 Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Morere J-F. Microsatellite instability: a predictive marker in metastatic colorectal cancer?. Target Oncol 2009; 4 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 59 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
    CrossrefPubMedGoogle Scholar
  • 60 Snyder A, Makarov V, Merghoub T. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371 (23) 2189-2199
    CrossrefPubMedGoogle Scholar
  • 61 Rizvi NA, Hellmann MD, Snyder A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348 (6230): 124-128
    CrossrefPubMedGoogle Scholar
  • 62 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357 (6349): 409-413
    CrossrefPubMedGoogle Scholar
  • 63 Le DT, Kim TW, Van Cutsem E. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 2020; 38 (01) 11-19
    CrossrefPubMedGoogle Scholar
  • 64 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18 (09) 1182-1191
    CrossrefPubMedGoogle Scholar
  • 65 FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer. Accessed June 4, 2023 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer
    PubMedGoogle Scholar
  • 66 Overman MJ, Lonardi S, Wong KYM. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36 (08) 773-779
    CrossrefPubMedGoogle Scholar
  • 67 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359 (6382): 1350-1355
    CrossrefPubMedGoogle Scholar
  • 68 FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer. Accessed June 4, 2023 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ipilimumab-msi-h-or-dmmr-metastatic-colorectal-cancer
    PubMedGoogle Scholar
  • 69 Lenz H-J, Van Cutsem E, Luisa Limon M. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 2022; 40 (02) 161-170
    CrossrefPubMedGoogle Scholar
  • 70 Hellmann MD, Rizvi NA, Goldman JW. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017; 18 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 71 Overman MJ, Lenz H-J, Andre T. et al. Nivolumab (NIVO)  ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): five-year follow-up from CheckMate 142. J Clin Oncol 2022; 40 (16) 3510-3510
    CrossrefPubMedGoogle Scholar
  • 72 FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. Accessed June 4, 2023 at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer
    PubMedGoogle Scholar
  • 73 Diaz Jr LA, Shiu K-K, Kim T-W. et al; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022; 23 (05) 659-670
    CrossrefPubMedGoogle Scholar
  • 74 Andre T, Braud FGD, Jimenez-Rodriguez B. et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: a post-hoc subgroup analysis of patients with colorectal cancer. J Clin Oncol 2022; 40 (04) 201
    CrossrefPubMedGoogle Scholar
  • 75 Verschoor YL, Van Den Berg J, Beets G. et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. J Clin Oncol 2022; 40 (16) 3511
    CrossrefPubMedGoogle Scholar
  • 76 Chalabi M, Verschoor YL, van den Berg J. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study (LBA7). Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedGoogle Scholar
  • 77 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
    CrossrefPubMedGoogle Scholar
  • 78 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
    CrossrefPubMedGoogle Scholar
  • 79 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
    CrossrefPubMedGoogle Scholar
  • 80 Meillan N, Vernerey D, Lefèvre JH. et al. Mismatch repair system deficiency is associated with response to neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2019; 105 (04) 824-833
    CrossrefPubMedGoogle Scholar
  • 81 Yuki S, Bando H, Tsukada Y. et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020; 38 (15) 4100-4100
    CrossrefPubMedGoogle Scholar
  • 82 Cercek A, Lumish MA, Sinopoli JC. et al. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. J Clin Oncol 2022; 40 (17) LBA5-LBA5
    CrossrefPubMedGoogle Scholar
  • 83 Cercek A, Lumish M, Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386 (25) 2363-2376
    CrossrefPubMedGoogle Scholar
  • 84 André T, Overman M, Lonardi S. et al. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142. Ann Oncol 2017; 28: 484PD
    CrossrefPubMedGoogle Scholar
  • 85 Möller K, Blessin NC, Höflmayer D. et al. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta Oncol 2021; 60 (09) 1210-1217
    CrossrefPubMedGoogle Scholar
  • 86 Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol Hematol 2021; 157: 103147
    CrossrefPubMedGoogle Scholar
  • 87 NCT05064059. A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A–007). Accessed June 4, 2023 at: https://clinicaltrials.gov/ct2/show/NCT05064059
    PubMedGoogle Scholar
  • 88 NCT04326296: The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer. Accessed June 4, 2023 at: https://clinicaltrials.gov/ct2/show/NCT04326296
    PubMedGoogle Scholar
  • 89 NCT03711058. Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer. Accessed June 4, 2023 at: https://clinicaltrials.gov/ct2/show/NCT03711058
    PubMedGoogle Scholar
  • 90 Goodman AM, Kato S, Bazhenova L. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017; 16 (11) 2598-2608
    CrossrefPubMedGoogle Scholar
  • 91 Samstein RM, Lee CH, Shoushtari AN. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51 (02) 202-206
    CrossrefPubMedGoogle Scholar
  • 92 Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377 (25) 2500-2501
    CrossrefPubMedGoogle Scholar
  • 93 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 94 FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Accessed June 4, 2023 at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors
    PubMedGoogle Scholar
  • 95 Meiri E, Garrett-Mayer E, Halabi S. et al. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol 2020; 38 (04) 133-133
    CrossrefPubMedGoogle Scholar
  • 96 Antoniotti C, Korn WM, Marmorino F. et al. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: next-generation sequencing results of TRIBE2 study. Eur J Cancer 2021; 155: 73-84
    CrossrefPubMedGoogle Scholar
  • 97 Stahler A, Stintzing S, von Einem JC. et al. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: next-generation sequencing results of the FIRE-3 trial. Eur J Cancer 2020; 137: 250-259
    CrossrefPubMedGoogle Scholar
  • 98 Rousseau B, Foote MB, Maron SB. et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med 2021; 384 (12) 1168-1170
    CrossrefPubMedGoogle Scholar
  • 99 Vilar E, Mork ME, Cuddy A. et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 2014; 207 (10-12): 495-502
    CrossrefPubMedGoogle Scholar
  • 100 Hile SE, Shabashev S, Eckert KA. Tumor-specific microsatellite instability: do distinct mechanisms underlie the MSI-L and EMAST phenotypes?. Mutat Res 2013; 743-744: 67-77
    CrossrefPubMedGoogle Scholar
  • 101 Kikuchi T, Mimura K, Okayama H. et al. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett 2019; 18 (06) 5977-5985
    PubMedGoogle Scholar
  • 102 Lee HS, Park KU, Kim DW. et al. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) and microsatellite instability in patients with colorectal cancer and its clinical features. Curr Mol Med 2016; 16 (09) 829-839
    CrossrefPubMedGoogle Scholar
  • 103 Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel) 2015; 6 (02) 185-205
    CrossrefPubMedGoogle Scholar
  • 104 Watson MM, Kanani A, Lea D. et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) in colorectal cancer is associated with an elderly, frail phenotype and improved recurrence-free survival. Ann Surg Oncol 2020; 27 (04) 1058-1067
    CrossrefPubMedGoogle Scholar
  • 105 Chen MH, Chang SC, Lin PC. et al. Combined microsatellite instability and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) might be a more promising immune biomarker in colorectal cancer. Oncologist 2019; 24 (12) 1534-1542
    CrossrefPubMedGoogle Scholar
  • 106 Watson MM, Lea D, Rewcastle E, Hagland HR, Søreide K. Elevated microsatellite alterations at selected tetranucleotides in early-stage colorectal cancers with and without high-frequency microsatellite instability: same, same but different?. Cancer Med 2016; 5 (07) 1580-1587
    CrossrefPubMedGoogle Scholar
  • 107 Watson MM, Lea D, Gudlaugsson E, Skaland I, Hagland HR, Søreide K. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. Cancer Immunol Immunother 2020; 69 (08) 1627-1637
    CrossrefPubMedGoogle Scholar
  • 108 van den Bulk J, Verdegaal EME, Ruano D. et al. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Med 2019; 11 (01) 87
    CrossrefPubMedGoogle Scholar
  • 109 Yossef R, Tran E, Deniger DC. et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 2018; 3 (19) e122467
    CrossrefPubMedGoogle Scholar
  • 110 Wang F, Zhao Q, Wang YN. et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 2019; 5 (10) 1504-1506
    CrossrefPubMedGoogle Scholar
  • 111 Palles C, Martin L, Domingo E. et al; CORGI Consortium. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. Fam Cancer 2022; 21 (02) 197-209
    CrossrefPubMedGoogle Scholar
  • 112 Rousseau B, Vidal J, Diaz Jr LA. Evaluation of POLE/POLD1 variants as potential biomarkers for immune checkpoint inhibitor treatment outcomes. JAMA Oncol 2020; 6 (04) 589-590
    CrossrefPubMedGoogle Scholar
  • 113 Rousseau B, Bieche I, Pasmant E. et al. PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov 2022; 12 (06) 1435-1448
    CrossrefPubMedGoogle Scholar
  • 114 Garmezy B, Gheeya J, Lin HY. et al. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol 2022; 6: e2100267
    CrossrefPubMedGoogle Scholar
  • 115 Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw 2017; 15 (02) 142-147
    CrossrefPubMedGoogle Scholar
  • 116 Chen J, Lou H. Complete response to pembrolizumab in advanced colon cancer harboring somatic POLE F367S mutation with microsatellite stability status: a case study. OncoTargets Ther 2021; 14: 1791-1796
    CrossrefPubMedGoogle Scholar
  • 117 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (05) 646-674
    CrossrefPubMedGoogle Scholar
  • 118 Moretto R, Elliott A, Zhang J. et al. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. J Natl Cancer Inst 2022; 114 (02) 271-279
    CrossrefPubMedGoogle Scholar
  • 119 Winer EP, Lipatov O, Im SA. et al; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (04) 499-511
    CrossrefPubMedGoogle Scholar
  • 120 Matulonis UA, Shapira-Frommer R, Santin AD. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 2019; 30 (07) 1080-1087
    CrossrefPubMedGoogle Scholar
  • 121 Markkanen E, Dorn J, Hübscher U. MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA. Front Genet 2013; 4: 18
    CrossrefPubMedGoogle Scholar
  • 122 Kairupan C, Scott RJ. Base excision repair and the role of MUTYH. Hered Cancer Clin Pract 2007; 5 (04) 199-209
    CrossrefPubMedGoogle Scholar
  • 123 Nielsen M, de Miranda NF, van Puijenbroek M. et al. Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer 2009; 9: 184
    CrossrefPubMedGoogle Scholar
  • 124 Zhang QM, Dianov GL. DNA repair fidelity of base excision repair pathways in human cell extracts. DNA Repair (Amst) 2005; 4 (02) 263-270
    CrossrefPubMedGoogle Scholar
  • 125 de Miranda NF, Nielsen M, Pereira D. et al. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers. J Pathol 2009; 219 (01) 69-76
    CrossrefPubMedGoogle Scholar
  • 126 Volkov NM, Yanus GA, Ivantsov AO. et al. Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. Invest New Drugs 2020; 38 (03) 894-898
    CrossrefPubMedGoogle Scholar